| Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer M Moutafi, CJ Robbins, V Yaghoobi, AI Fernandez, S Martinez-Morilla, ... Laboratory Investigation 102 (10), 1101-1108, 2022 | 74 | 2022 |
| Differentially expressed genes and signature pathways of human prostate cancer JS Myers, AK von Lersner, CJ Robbins, QXA Sang PloS one 10 (12), e0145322, 2015 | 47 | 2015 |
| Severe epididymo‐orchitis and encephalitis complicating anti‐PD‐1 therapy HT Quach, CJ Robbins, JM Balko, CY Chiu, S Miller, MR Wilson, ... The oncologist 24 (7), 872-876, 2019 | 38 | 2019 |
| Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry CJ Robbins, AI Fernandez, G Han, S Wong, M Harigopal, M Podoll, ... Modern Pathology 36 (1), 100032, 2023 | 34 | 2023 |
| An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability CE Hayford, DR Tyson, CJ Robbins III, PL Frick, V Quaranta, LA Harris PLoS Biology 19 (6), e3000797, 2021 | 32 | 2021 |
| An integrative gene expression and mathematical flux balance analysis identifies targetable redox vulnerabilities in melanoma cells BB Paudel, JE Lewis, KN Hardeman, CE Hayford, CJ Robbins, ... Cancer research 80 (20), 4565-4577, 2020 | 16 | 2020 |
| Decoding somatic driver gene mutations and affected signaling pathways in human medulloblastoma subgroups CJ Robbins, MJ Bou-Dargham, K Sanchez, MC Rosen, QXA Sang Journal of Cancer 9 (24), 4596, 2018 | 14 | 2018 |
| Multi-institutional study of pathologist reading of the programmed cell death ligand-1 combined positive score immunohistochemistry assay for gastric or gastroesophageal … AI Fernandez, CJ Robbins, P Gaule, D Agostini-Vulaj, RA Anders, ... Modern Pathology 36 (5), 100128, 2023 | 11 | 2023 |
| Sub-chronic administration of LY294002 sensitizes cervical cancer cells to chemotherapy by enhancing mitochondrial JNK signaling TP Chambers, GM Portalatin, I Paudel, CJ Robbins, JW Chambers Biochemical and Biophysical Research Communications 463 (4), 538-544, 2015 | 11 | 2015 |
| Development of an immunohistochemical assay for Siglec-15 S Shafi, TN Aung, C Robbins, J Zugazagoitia, I Vathiotis, N Gavrielatou, ... Laboratory Investigation 102 (7), 771-778, 2022 | 10 | 2022 |
| PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC). DB Doroshow, W Wei, J Zugazagoitia, CJ Robbins, S Gupta, ... Journal of Clinical Oncology 38 (15_suppl), 9539-9539, 2020 | 5 | 2020 |
| Multi-institutional study of pathologist reading of the PD-L1 combined positive score (CPS) immunohistochemistry assay in gastric or gastroesophageal junction cancer AI Fernandez, CJ Robbins, P Gaule, D Agostini-Vulaj, RA Anders, ... Modern pathology: an official journal of the United States and Canadian …, 2023 | 1 | 2023 |
| Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay M Liu, I Vathiotis, CJ Robbins, NNN Chan, M Moutafi, S Burela, V Xirou, ... Modern Pathology 37 (9), 100556, 2024 | | 2024 |
| Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores CJ Robbins, AI Fernandez, DL Rimm JAMA oncology 9 (9), 1298-1299, 2023 | | 2023 |
| Real-time luminescence enables continuous drug–response analysis in adherent and suspension cell lines CM Wandishin, CJ Robbins, DR Tyson, LA Harris, V Quaranta Cancer Biology & Therapy 23 (1), 358-368, 2022 | | 2022 |
| Applying Deep Learning Cancer Subtyping Algorithms Trained on Physical Slides to Multiphoton Imaging of Unembedded Samples F Mahmood, CJ Robbins, S Perincheri, R Torres American Journal of Clinical Pathology 158 (Supplement_1), S117-S117, 2022 | | 2022 |